1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the Market 25
2.2 Major Growth Drivers 27
2.3 Market Restraints and Challenges 32
2.4 Emerging Opportunities and Market Trends 35
2.5 Porters Fiver Forces Analysis 39
3 Segmentation of Europe Market by Product Type 43
3.1 Market Overview by Product Type 43
3.2 Recombinant Non-glycosylated Biosimilars 45
3.2.1 Insulin 47
3.2.2 Recombinant Human Growth Hormone (rHGH) 48
3.2.3 Granulocyte Colony Stimulating Factor 49
3.2.4 Interferon 50
3.3 Recombinant Glycosylated Biosimilars 51
3.3.1 Monoclonal Antibodies (mAb) 52
3.3.2 Erythropoietin (EPO) 53
3.3.3 Follicle Stimulating Hormone 54
3.4 Recombinant Peptides and Others 55
3.4.1 Tumor Necrosis Factor (TNF)-Inhibitor 56
3.4.2 Parathyroid Hormone 57
3.4.3 Enzymes, Immunomodulators, GnRH Analogs and Others 58
4 Segmentation of Europe Market by Indication 59
4.1 Market Overview by Indication 59
4.2 Cancer 61
4.3 Autoimmune Disease 62
4.4 Blood Disorder 63
4.5 Diabetes 64
4.6 Growth Hormone Deficiency 65
4.7 Infectious Diseases 66
4.8 Other Indications 67
5 Segmentation of Europe Market by Manufacturing 68
5.1 Market Overview by Manufacturing 68
5.2 Contract Manufacturing 70
5.3 Inhouse Manufacturing 71
6 Segmentation of Europe Market by End User 72
6.1 Market Overview by End User 72
6.2 Hospitals and Clinics 74
6.3 Research Institutes 75
6.4 Other End Users 76
7 European Market 2019-2030 by Country 77
7.1 Overview of European Market 77
7.2 Germany 82
7.3 U.K. 85
7.4 France 88
7.5 Spain 90
7.6 Italy 92
7.7 Russia 94
7.8 Rest of European Market 96
8 Competitive Landscape 98
8.1 Overview of Key Vendors 98
8.2 New Product Launch, Partnership, Investment, and M&A 102
8.3 Company Profiles 103
AMEGA Biotech S.A. 103
Apotex Inc. 105
Biocon Ltd 106
Biogen Inc. 107
Boehringer Ingelheim 108
Celltrion, Inc. 109
Dr. Reddys Laboratories Ltd. 110
Eli Lilly and Company 111
Intas Pharmaceuticals Ltd. 112
LG Chem, Ltd. 113
Merck and Co. Inc. 114
Mylan N.V. 115
Pfizer Inc. 116
Samsung Biologics Co., Ltd. 117
Sandoz International GmbH 118
STADA Arzneimittel AG 119
Teva Pharmaceutical Industries Ltd. 120
RELATED REPORTS 121